Show simple item record

Treatment-related leukaemia--a clinical and scientific challenge.

dc.contributor.authorNg, Antony
dc.contributor.authorTaylor, G Malcolm
dc.contributor.authorEden, Tim O B
dc.date.accessioned2009-11-19T17:10:53Z
dc.date.available2009-11-19T17:10:53Z
dc.date.issued2000-10
dc.identifier.citationTreatment-related leukaemia--a clinical and scientific challenge. 2000, 26 (5):377-91 Cancer Treat. Rev.en
dc.identifier.issn0305-7372
dc.identifier.pmid11006138
dc.identifier.doi10.1053/ctrv.2000.0186
dc.identifier.urihttp://hdl.handle.net/10541/86527
dc.description.abstractThe development of a second tumour, including treatment-related leukaemia (TRL), is the most devastating complication of intensive cancer chemotherapy. This is especially relevant in the paediatric population as over 70% of children diagnosed with a malignancy will now live at least 5 years. Most TRLs are myeloid leukaemias and carry an overall poor prognosis when compared with their de novo counterparts. Despite the well known association with specific cytotoxic agents, improved understanding of the pathogenesis and risk factors of TRL is ultimately essential if we are to develop successful strategies for prevention and treatment. Here we review these aspects, together with the clinical and diverse biological features of this complication and the efficacy of current therapy.
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subjectSecond Primary Canceren
dc.subjectRadiation-Induced Leukaemiaen
dc.subject.meshAntineoplastic Agents, Alkylating
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshEnzyme Inhibitors
dc.subject.meshGenetic Predisposition to Disease
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshLeukemia
dc.subject.meshLeukemia, Radiation-Induced
dc.subject.meshNeoplasms, Second Primary
dc.subject.meshPrognosis
dc.subject.meshRisk Factors
dc.titleTreatment-related leukaemia--a clinical and scientific challenge.en
dc.typeArticleen
dc.contributor.departmentImmunogenetics Laboratory, St Mary's Hospital, Hathersage Road, Manchester M13 OJH, UK.en
dc.identifier.journalCancer Treatment Reviewsen
html.description.abstractThe development of a second tumour, including treatment-related leukaemia (TRL), is the most devastating complication of intensive cancer chemotherapy. This is especially relevant in the paediatric population as over 70% of children diagnosed with a malignancy will now live at least 5 years. Most TRLs are myeloid leukaemias and carry an overall poor prognosis when compared with their de novo counterparts. Despite the well known association with specific cytotoxic agents, improved understanding of the pathogenesis and risk factors of TRL is ultimately essential if we are to develop successful strategies for prevention and treatment. Here we review these aspects, together with the clinical and diverse biological features of this complication and the efficacy of current therapy.


This item appears in the following Collection(s)

Show simple item record